Small E - Search Results

1

Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901.

Stadler WM, Rosner G, Small E, Hollis D, Rini B, Zaentz SD, Mahoney J, Ratain MJ. Stadler WM, et al. Among authors: small e. J Clin Oncol. 2005 Jun 1;23(16):3726-32. doi: 10.1200/JCO.2005.44.150. J Clin Oncol. 2005. PMID: 15923569 Clinical Trial.

2

Malignant germ cell tumors in men infected with the human immunodeficiency virus: natural history and results of therapy.

Timmerman JM, Northfelt DW, Small EJ. Timmerman JM, et al. Among authors: small ej. J Clin Oncol. 1995 Jun;13(6):1391-7. doi: 10.1200/JCO.1995.13.6.1391. J Clin Oncol. 1995. PMID: 7538557

3

Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A Southwest Oncology Group Study.

Hussain M, Fisher EI, Petrylak DP, O'Connor J, Wood DP, Small EJ, Eisenberger MA, Crawford ED. Hussain M, et al. Among authors: small ej. J Clin Oncol. 2000 Mar;18(5):1043-9. doi: 10.1200/JCO.2000.18.5.1043. J Clin Oncol. 2000. PMID: 10694555 Clinical Trial.

4

Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone.

Small EJ, Meyer M, Marshall ME, Reyno LM, Meyers FJ, Natale RB, Lenehan PF, Chen L, Slichenmyer WJ, Eisenberger M. Small EJ, et al. J Clin Oncol. 2000 Apr;18(7):1440-50. doi: 10.1200/JCO.2000.18.7.1440. J Clin Oncol. 2000. PMID: 10735891 Clinical Trial.

5

Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point.

Small EJ, Lew D, Redman BG, Petrylak DP, Hammond N, Gross HM, Eastham JA, Crawford ED. Small EJ, et al. J Clin Oncol. 2000 Jul;18(13):2537-44. doi: 10.1200/JCO.2000.18.13.2537. J Clin Oncol. 2000. PMID: 10893284 Clinical Trial.

6

Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival.

Small EJ, McMillan A, Meyer M, Chen L, Slichenmyer WJ, Lenehan PF, Eisenberger M. Small EJ, et al. J Clin Oncol. 2001 Mar 1;19(5):1304-11. doi: 10.1200/JCO.2001.19.5.1304. J Clin Oncol. 2001. PMID: 11230472 Clinical Trial.

7

An update on prostate cancer.

Rini BI, Small EJ. Rini BI, et al. Among authors: small ej. Curr Opin Oncol. 2001 May;13(3):204-11. doi: 10.1097/00001622-200105000-00013. Curr Opin Oncol. 2001. PMID: 11307066 Review.

8

Immunotherapy for prostate cancer.

Rini BI, Small EJ. Rini BI, et al. Among authors: small ej. Curr Oncol Rep. 2001 Sep;3(5):418-23. doi: 10.1007/s11912-001-0028-1. Curr Oncol Rep. 2001. PMID: 11489243 Review.

9

Prostate cancer update.

Rini BI, Small EJ. Rini BI, et al. Curr Opin Oncol. 2002 May;14(3):286-91. doi: 10.1097/00001622-200205000-00006. Curr Opin Oncol. 2002. PMID: 11981273 Review.

10

Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.

Small EJ, Halabi S, Ratain MJ, Rosner G, Stadler W, Palchak D, Marshall E, Rago R, Hars V, Wilding G, Petrylak D, Vogelzang NJ. Small EJ, et al. J Clin Oncol. 2002 Aug 15;20(16):3369-75. doi: 10.1200/JCO.2002.10.022. J Clin Oncol. 2002. PMID: 12177096 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

802 results

Search Page

Filters